What is Viriom?
Viriom Inc. is a biopharmaceutical company dedicated to developing effective and affordable treatments for critical global diseases, with a strategic focus on infectious diseases, particularly viral conditions affecting the blood and respiratory systems, as well as solid tumors in oncology. Leveraging a robust network of partnerships, Viriom is building a comprehensive global drug development platform designed to improve access to innovative therapies in both developed and developing nations. The company's core mission is to ensure that life-saving treatments are accessible to all populations worldwide.
How much funding has Viriom raised?
Viriom has raised a total of $7M across 2 funding rounds:
Private Equity
$2.4M
Other Financing Round
$4.7M
Private Equity (2016): $2.4M with participation from The Skolkovo Foundation
Other Financing Round (2016): $4.7M led by The Skolkovo Foundation
Key Investors in Viriom
The Skolkovo Foundation
The Skolkovo Foundation is a Russian non-profit organization focused on accelerating innovation-based economic transformation. It supports high-tech startups and fosters an ecosystem for technology entrepreneurship.
What's next for Viriom?
The recent major strategic investment signals Viriom's transition into a scaling phase, likely focused on accelerating clinical trials, expanding manufacturing capabilities, and broadening market reach for its therapeutic candidates. This enterprise-level funding will be instrumental in navigating the complex regulatory pathways and commercialization efforts required to bring novel treatments to patients globally, particularly in underserved regions. Viriom's commitment to accessible healthcare positions it as a key player in addressing unmet medical needs.
See full Viriom company page
